IDEXX Laboratories slides as investors weigh analyst target cuts and executive reshuffle ahead of 2026 priorities

IDEXX Laboratories, Inc. (IDXX) is down 4.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears tied to a mix of renewed Wall Street caution on the 2026 outlook and fresh attention on leadership and organizational changes. With the stock still viewed as a premium-valued animal health diagnostics name, incremental negatives like lowered price targets and executive departures can pressure sentiment even without a single “headline” earnings miss.

Details:

A sell-side analyst recently lowered its price target on IDEXX while keeping a positive long-term view, which can still spark short-term de-risking when investors focus on near-term growth and margin assumptions.

IDEXX disclosed that EVP Nimrata Hunt (Global Strategy and Commercial) will exit effective April 13, 2026, with the role eliminated and the separation treated as a termination without cause.

The same filing noted Hunt may remain available as a special advisor on an as-needed basis through July 13, 2026, and it outlined separation-related benefits.

Separately, IDEXX has also outlined a planned CEO transition with the new CEO expected to take over on May 12, 2026, which can keep attention on execution risk during the handoff.

Sources:

IDEXX Investor Relations (SEC filings), StockTitan, StreetInsider

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IDXX Insider Trading Activity

$IDXX insiders have traded $IDXX stock on the open market 35 times in the past 6 months. Of those trades, 0 have been purchases and 35 have been sales.

Here’s a breakdown of recent trading of $IDXX stock by insiders over the last 6 months:

JONATHAN JAY MAZELSKY (President and CEO) has made 0 purchases and 13 sales selling 23,326 shares for an estimated $15,338,080.
NIMRATA HUNT (Executive Vice President) has made 0 purchases and 6 sales selling 13,876 shares for an estimated $9,526,121.
GEORGE FENNELL (Executive Vice President) has made 0 purchases and 8 sales selling 11,345 shares for an estimated $7,336,993.
MICHAEL G ERICKSON (Executive Vice President) has made 0 purchases and 6 sales selling 5,371 shares for an estimated $3,369,666.
SOPHIE V. VANDEBROEK has made 0 purchases and 2 sales selling 1,464 shares for an estimated $920,293.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$IDXX Hedge Fund Activity

We have seen 599 institutional investors add shares of $IDXX stock to their portfolio, and 565 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ELYXIUM WEALTH, LLC added 5,419,507 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,666,459,070
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,642,309 shares (-75.4%) from their portfolio in Q4 2025, for an estimated $1,787,601,307
J. STERN & CO. LLP added 2,642,200 shares (+23694.7%) to their portfolio in Q4 2025, for an estimated $1,787,527,566
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 1,442,174 shares (+63503.9%) to their portfolio in Q4 2025, for an estimated $975,673,976
FUNDSMITH LLP removed 734,422 shares (-28.1%) from their portfolio in Q4 2025, for an estimated $496,858,515
WELLINGTON MANAGEMENT GROUP LLP added 592,834 shares (+318.1%) to their portfolio in Q4 2025, for an estimated $401,069,986
MACQUARIE GROUP LTD removed 509,777 shares (-96.8%) from their portfolio in Q4 2025, for an estimated $344,879,433

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$IDXX Congressional Stock Trading

Members of Congress have traded $IDXX stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $IDXX stock by members of Congress over the last 6 months:

REPRESENTATIVE APRIL MCCLAIN DELANEY has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 01/13, 10/16.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$IDXX Analyst Ratings

Wall Street analysts have issued reports on $IDXX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/03/2026
Morgan Stanley issued a "Overweight" rating on 11/04/2025
Stifel issued a "Buy" rating on 10/31/2025

To track analyst ratings and price targets for $IDXX, check out Quiver Quantitative's $IDXX forecast page.

$IDXX Price Targets

Multiple analysts have issued price targets for $IDXX recently. We have seen 7 analysts offer price targets for $IDXX in the last 6 months, with a median target of $775.0.

Here are some recent targets:

Jonathan Block from Stifel set a target price of $675.0 on 03/31/2026
David Westenberg from Piper Sandler set a target price of $750.0 on 02/09/2026
Glen Santangelo from Barclays set a target price of $800.0 on 02/05/2026
Mark Massaro from BTIG set a target price of $800.0 on 02/03/2026
Andrea Alfonso from UBS set a target price of $730.0 on 02/03/2026
Chris Schott from JP Morgan set a target price of $775.0 on 11/04/2025
Erin Wright from Morgan Stanley set a target price of $805.0 on 11/04/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.